Investigating how a blood factor interacts with platelets during clot formation
Official title: Coagulation Factor XII Recruitment and Activation During Thrombus Formation
Funded at Beth Israel Deaconess Medical Center · NIH-10914894 · Data updated 2026-11-12
This study is looking at how a protein called factor XII affects blood clotting and how blocking it might help create new medicines that prevent clots without causing bleeding, which could be really helpful for people with blood clotting problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $685,969 |
| NIH project number | 5R01HL166246-02 |
| Project ID | NIH-10914894 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with coagulation disorders or those at risk of thrombosis who are seeking safer treatment options.
✕Less likely to help
Patients who do not have coagulation disorders or are not at risk for thrombosis may not receive any benefit from this research.
What this research studies
This research focuses on understanding the role of coagulation factor XII (FXII) in blood clot formation and how it interacts with platelets. The study aims to explore how inhibiting FXII could lead to new antithrombotic medications that prevent blood clots without increasing the risk of bleeding. By using advanced techniques like mass spectrometry, researchers will identify the specific interactions between FXII and platelet receptors, which could pave the way for safer treatments for coagulation disorders. Patients may benefit from insights that could lead to innovative therapies for managing blood clotting issues.
Why it matters
Potential benefit: If successful, this research could lead to new medications that effectively prevent blood clots without the risk of bleeding complications.
How similar studies have gone: Previous research has shown promise in targeting coagulation factor XII for antithrombotic therapies, indicating that this approach may be viable.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Bendapudi, Pavan — Beth Israel Deaconess Medical Center
- Study coordinator: Bendapudi, Pavan
Related research
Other NIH-funded projects on the same topics.
-
SATURN MRI ancillary study: statins after intracerebral hemorrhage and brain MRI markers
This study looks at what happens to brain MRI markers and health outcomes when people with a specific type of brain bleed continue or stop taking statins.
-
Statin use after brain bleed MRI study in ICH patients (SATURN MRI) Ancillary Study
This project tests whether continuing or stopping statin therapy after an intracerebral hemorrhage affects brain changes seen on MRI and related health outcomes in people with lobar ICH.
-
Statin use after brain bleed: SATURN MRI ancillary study
This project tests whether continuing statin medicines after a brain bleed (lobar intracerebral hemorrhage) affects new brain blood vessel findings and long-term health.
-
XenCAT: Single Cell Atlas for Xenopus
Aims to map gene activity at the single-cell level in Xenopus to help understand how cells develop and how this relates to human disease.
-
Statin use after lobar intracerebral hemorrhage
This trial compares continuing versus stopping statins in people who had a lobar intracerebral hemorrhage to see how that affects repeat brain bleeds, strokes, heart attacks, and recovery over two years.
-
Statin use after lobar brain hemorrhage
This trial compares stopping versus continuing statin medicine in people who had a lobar brain bleed to learn effects on repeat bleeding and future heart or stroke events.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.